Vaccination With Autologous Dendritic Cells Pulsed With Tumor Antigens for Treatment of Patients With Renal Cell Carcinoma.A Phase I/II Study.
Eligible patients receive vaccination with tumor antigen pulsed autologous monocyte-derived
mature dendritic cells with a fixed interval. The dendritic cells are generated from
leukapheresis products and frozen after antigen loading.
HLA A2 positive patients are treated with PADRE and oncopeptide pulsed DC; survivin and
telomerase peptides. HLA A2 negative patients are treated with KLH and tumorlysate pulsed
DC; autologous or allogeneic. Each patient is given 6 immunizations with at least 5x106
peptide/lysate pulsed autologous DC. Vaccination 1-4 is given weekly and 4-6 at 2-week
intervals. Those patients who exhibit stable disease, partial response or complete response
after 6 injections will be given 4 more vaccinations at 2-week interval. The vaccine is
applied by intradermal injection near the inguinal region. IL-2 2 MIU s.c. day 2-6 and
Thymosin alpha 1 (Zadaxin®, SciClone) 1,6 mg s.c. twice a week are used for adjuvants. Scans
and re-staging tests are performed at scheduled intervals throughout the study.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary aim of the study is to evaluate tolerability and safety of the treatment.
weekly for the first four weeks, thereafter biweekly
Inge Marie Svane, MD, PHD
Department of Oncology, Copenhagen University Hospital, Herlev, Herlev Ringvej 75, DK-2730 Herlev, Denmark
Denmark: Danish Medicines Agency